Caffeine for Excessive Daytime Somnolence in Parkinson's Disease

Caffeine for Excessive Daytime Somnolence in Parkinson's Disease

Patrocinadores

Patrocinador principal: Ron Postuma

Colaborador: Canadian Institutes of Health Research (CIHR)
University of Toronto

Fuente McGill University Health Centre/Research Institute of the McGill University Health Centre
Resumen breve

Many patients with Parkinson's disease (PD) have sleep problems, including excessive sleepiness during the day. This is probably due to degeneration of sleep-regulating areas in the brain. At present, the only treatment for sleepiness in PD is modafinil, which is expensive and only partially effective. There is another potential treatment for sleepiness that is used worldwide, is inexpensive, well tolerated and safe - namely, caffeine. There have also been suggestions that caffeine may slow the progression of degeneration in PD, since coffee non-drinkers are at higher risk of developing PD. PD patients, even with severe sleepiness often do not use caffeine. It is unclear whether this is because their PD makes their sleepiness unresponsive to caffeine, because they cannot tolerate it, or whether this reflects their lifelong habit of non-use. This proposal outlines a trial in which patients with excessive sleepiness will be given caffeine or placebo (no therapy) in a blinded fashion. In this way, the effect of caffeine on sleepiness and motor symptoms can be directly analyzed. In addition, these findings can be used to test the tolerability of caffeine, to help plan a larger-scale study testing whether caffeine can slow the progression of PD

Descripción detallada

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by motor disability and many disabling non-motor symptoms. Excessive daytime somnolence (EDS) is found in up to 50% of patients with PD, and can cause considerable impairment of quality of life. At present, the only proven treatment for EDS in PD is modafinil, an alerting agent with an unknown mechanism of action. However, modafinil is only moderately effective and is very expensive. Caffeine is a very well tolerated and inexpensive alerting agent that is used worldwide, but very few patients with PD use it as therapy for EDS. It is unclear whether this is because it does not help EDS in PD, has side effects, or simply has not been considered because of lifelong patterns of non-use.

If caffeine can be demonstrated as an effective agent for EDS in PD, it will likely become the first-line agent for EDS. This will result in considerable cost savings for patients and health care payers, as well as potentially helping those who cannot tolerate, do not respond to, or cannot afford modafinil.

Another compelling question of interest to patients with PD is whether caffeine may be neuroprotective. Despite intensive research, no treatment has been found that can slow the progression of neurodegeneration in PD. Recently numerous epidemiologic studies have linked lifelong use of caffeine to a lower risk of PD. Although the mechanism for this finding is unclear, supporting evidence from animal models suggests that a true neuroprotective benefit of caffeine is a strong possibility. Alternatively, caffeine could have a benefit on motor manifestations of PD, which would prevent diagnosis of PD. Any finding of a symptomatic benefit of caffeine on motor manifestations of PD will have obvious and important implications for treatment of persons affected with PD and for planning of neuroprotective trials. Any finding of a neuroprotective benefit of caffeine will almost certainly result in its immediate widespread use in PD, with profound implications for patient care.

The present proposal is for a double blind randomized placebo controlled crossover trial that will answer three important questions in PD: is caffeine useful for the treatment of EDS in patients with PD? does caffeine have any symptomatic effect on the motor manifestations of PD? and, does caffeine have an acceptable tolerability and side effect profile that will allow planning of an eventual neuroprotective trial? Patients with PD who have EDS with an Epworth sleepiness scale of >10 will be randomized to caffeine therapy (100 mg twice per day for three weeks, then 200 mg twice per day for three weeks) or placebo. A final assessment will be performed after a 4-week washout. A total of 52 patients will be randomized over a two-year period. The primary outcome measure will be the change in Epworth sleepiness scale between patients receiving caffeine versus placebo. Secondary outcome measures will include other sleep scales, tolerability measures, and measures of motor function and overall quality of life. After tests to assess normal distribution, analysis will be with two-sample t-test.

Estado general Completed
Fecha de inicio April 2007
Fecha de Terminación July 2011
Fecha de finalización primaria July 2011
Fase Phase 2/Phase 3
Tipo de estudio Interventional
Resultado primario
Medida Periodo de tiempo
Change in Epworth Sleepiness Scale 3 weeks
Resultado secundario
Medida Periodo de tiempo
Unified Parkinson Disease Rating Scale 3 weeks
Clinical Global Impression of Change 3 weeks
Pittsburgh Sleep Quality Index 3 weeks
Fatigue Severity Scale 3 weeks
Stanford Sleep Scale 3 weeks
PDQ-39 3 weeks
SF-36 3 weeks
Tolerability of Caffeine 3 weeks
Beck Depression Inventory 3 weeks
Inscripción 58
Condición
Intervención

Tipo de intervención: Drug

Nombre de intervención: Caffeine 100-200 mg BID

Descripción: Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo

Etiqueta de grupo de brazo: Caffeine

Tipo de intervención: Drug

Nombre de intervención: placebo

Descripción: placebo

Etiqueta de grupo de brazo: Placebo

Elegibilidad

Criterios:

Inclusion Criteria:

- A diagnosis of idiopathic PD

- Excessive daytime somnolence (defined as an Epworth sleepiness scale score of >10).

Exclusion Criteria:

- Estimated daily caffeine intake of more than 200 mg per day

- Active peptic ulcer disease

- Supraventricular cardiac arrhythmia (such as atrial fibrillation or atrial flutter)

- Uncontrolled hypertension - defined as systolic bp >170 or diastolic bp >110 on two consecutive readings

- EDS is caused by sleep apnea, restless legs syndrome, narcolepsy, shift work, or sleep promoting agents.

- Current use of prescribed alerting agents such as modafinil and methylphenidate

- Pre-menopausal women who are not using effective methods of birth control

- Dementia, defined as MMSE <24/30 and ADL impairment secondary to cognitive loss, or inability to understand consent process

- Depression, as defined by a Beck Depression Inventory score of >15.

- Changes to antiparkinsonian medication in the last 3 months, or changes to antiparkinsonian medication are anticipated during the study protocol.

Género: All

Edad mínima: 18 Years

Edad máxima: N/A

Voluntarios Saludables: No

Oficial general
Apellido Papel Afiliación
Ron Postuma, MD, MSc Principal Investigator Montreal General Hospital
Ubicación
Instalaciones:
Toronto Western Hospital | Toronto, Ontario, Canada
Montreal General Hospital | Montreal, Quebec, H3G 1A4, Canada
Ubicacion Paises

Canada

Fecha de verificación

April 2015

Fiesta responsable

Tipo: Sponsor-Investigator

Afiliación del investigador: McGill University Health Centre/Research Institute of the McGill University Health Centre

Nombre completo del investigador: Ron Postuma

Título del investigador: Neurologist

Palabras clave
Tiene acceso ampliado No
Condición Examinar
Número de brazos 2
Grupo de brazo

Etiqueta: Placebo

Tipo: Placebo Comparator

Etiqueta: Caffeine

Tipo: Experimental

Información de diseño del estudio

Asignación: Randomized

Modelo de intervención: Parallel Assignment

Propósito primario: Treatment

Enmascaramiento: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Fuente: ClinicalTrials.gov